14,559 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Symmetry Investments LP

Symmetry Investments LP acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 14,559 shares of the life sciences company’s stock, valued at approximately $1,520,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Illumina by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock worth $2,505,409,000 after purchasing an additional 66,528 shares in the last quarter. Edgewood Management LLC boosted its holdings in Illumina by 4.6% in the fourth quarter. Edgewood Management LLC now owns 6,878,495 shares of the life sciences company’s stock worth $957,762,000 after acquiring an additional 302,222 shares in the last quarter. Baillie Gifford & Co. grew its stake in shares of Illumina by 8.7% in the first quarter. Baillie Gifford & Co. now owns 5,736,418 shares of the life sciences company’s stock worth $787,725,000 after acquiring an additional 460,649 shares during the last quarter. WCM Investment Management LLC increased its holdings in shares of Illumina by 2,232.3% during the first quarter. WCM Investment Management LLC now owns 3,377,221 shares of the life sciences company’s stock valued at $463,760,000 after acquiring an additional 3,232,418 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Illumina by 7.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock worth $317,267,000 after purchasing an additional 204,043 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 2.4 %

Shares of NASDAQ:ILMN opened at $131.20 on Friday. The company has a 50-day moving average price of $125.25 and a 200 day moving average price of $120.67. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $148.19. The company has a market cap of $20.90 billion, a price-to-earnings ratio of -16.10 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.24. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The company’s revenue for the quarter was down 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 3.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ILMN shares. Scotiabank reduced their price objective on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research note on Thursday, August 15th. Piper Sandler decreased their price objective on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Jefferies Financial Group started coverage on Illumina in a research note on Monday, June 3rd. They set a “hold” rating and a $115.00 target price on the stock. Robert W. Baird boosted their price target on Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday, July 10th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $151.05.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.